top of page

Technetium-99m

Flat bottom of Erlenmeyer flask_edited.jpg
Image by Bosco Shots

Why Technetium-99m?

Technetium-99m is the most widely used medical isotope in the world, powering approximately 80% of all nuclear medicine scans. Every day, hospitals rely on Tc-99m for essential diagnostic procedures, including:

 

  • Cardiac Imaging: Assessing blood flow and heart function.

     

  • Bone Scans: Detecting fractures, infections, and metastasis.

     

  • Kidney Function: Evaluating renal perfusion and drainage.

     

  • Cancer Staging: Mapping the spread of disease for precise treatment planning.

Technical Snapshot

Isotope: Technetium-99m (Tc-99m)

Half-life: ~6 hours (Parent Mo-99: ~66 hours)

Decay Mode: Gamma emission (140 keV)

Key Reaction: Mo-100(γ,n) → Mo-99→Tc-99m

Primary Use: Diagnostic SPECT imaging (Cardiac, Bone, Renal, Oncology)

_edited.jpg

The Problem: A Vulnerable Global Supply

The world currently relies on a handful of aging nuclear reactors to produce molybdenum-99 (Mo-99), the "parent" isotope of technetium. This model carries two major risks:
 

  1. Supply Fragility: Maintenance shutdowns or transport disruptions at just one or two reactors can trigger global medical shortages, forcing hospitals to delay life-saving scans.
     

  2. Security Concerns: Reactor-based production historically relies on uranium fission, which involves complex regulatory, environmental, and security burdens.

The SCMR Solution: Strategic, Reactor-Free Backup

Southern Cross Medical Radioisotopes (SCMR) is establishing a sovereign, non-reactor production route to de-risk the Australian medical supply chain. By utilising high-power electron accelerators, we will produce Mo-99 directly from enriched molybdenum targets.
 

  • Uranium-Free: Our photonuclear pathway, Mo-100(γ,n) → Mo-99, avoids uranium fission entirely, eliminating HEU/LEU security issues and minimising nuclear waste.
     

  • Infrastructure Synergy: We use the same advanced accelerator infrastructure used for our therapeutic isotopes (Ac-225 and Cu-67), creating a highly efficient, dual-purpose production hub.
     

  • Sovereign Reliability: As a strategic regional supplier, SCMR ensures that Australian hospitals have a secure backup source of technetium, regardless of international reactor outages.

Verdict: Balancing Bulk and Precision

While traditional reactors are optimised for bulk yields, SCMR’s accelerator-based model focuses on high-value, high-purity, and high-security isotopes. By integrating Tc-99m into our portfolio, we provide a complete medical solution by supporting both the daily diagnostic needs of hospitals and the breakthrough therapeutic growth of precision oncology.

 

bottom of page